Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen

Shailja Tiwari, Sunil Kumar Verma, Govind P. Agrawal, Suresh P. Vyas

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The present work investigates prospective of recombinantly expressed influenza surface protein haemagglutinin (HA) complexed liposomes for intranasal delivery of HBsAg. Liposomes encapsulating HBsAg were prepared and complexed with HA. The prepared formulations were extensively characterized for vesicle size, polydispersity index, entrapment efficiency, HA complexation efficiency, in vitro release, etc. Stability of protein molecules was accessed by SDS-PAGE. The antigenicity of protein HBsAg was determined by EIA and the functional stability of HA was evaluated by haemagglutination assay. Subsequently, in vivo study was carried out to study their feasibility as nasal vaccine carriers. A significant and perdurable immune response was obtained following in vivo administration of the developed formulations that was comparable with alum adsorbed HBsAg administered intramuscularly. The HA complexed liposomal formulations elicited sIgA in mucosal secretions and also demonstrated cellular immune response both of which are not induced in the case of alum adsorbed HBsAg vaccine. Further, the HA complexed liposomes produced higher immune response as compared to plain liposomes that might be due to higher uptake of former as evidenced in microscopy study of nasal tissues. The higher cellular response generated by HA complexed liposomes may be possibly due to characteristic pH dependent fusion property of HA protein.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume413
Issue number1-2
DOIs
StatePublished - Jul 15 2011
Externally publishedYes

Fingerprint

Hemagglutinins
Viral Proteins
Hepatitis B Surface Antigens
Liposomes
Nose
Vaccines
Protein Stability
Hemagglutination
Feasibility Studies
Cellular Immunity
Human Influenza
Polyacrylamide Gel Electrophoresis
Microscopy
Membrane Proteins
Proteins

Keywords

  • HA
  • HBsAg
  • Liposomes
  • pH dependent fusion

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. / Tiwari, Shailja; Verma, Sunil Kumar; Agrawal, Govind P.; Vyas, Suresh P.

In: International Journal of Pharmaceutics, Vol. 413, No. 1-2, 15.07.2011, p. 211-219.

Research output: Contribution to journalArticle

Tiwari, Shailja ; Verma, Sunil Kumar ; Agrawal, Govind P. ; Vyas, Suresh P. / Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen. In: International Journal of Pharmaceutics. 2011 ; Vol. 413, No. 1-2. pp. 211-219.
@article{e3f9f710fbcc43dbacda16d5eebd9240,
title = "Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen",
abstract = "The present work investigates prospective of recombinantly expressed influenza surface protein haemagglutinin (HA) complexed liposomes for intranasal delivery of HBsAg. Liposomes encapsulating HBsAg were prepared and complexed with HA. The prepared formulations were extensively characterized for vesicle size, polydispersity index, entrapment efficiency, HA complexation efficiency, in vitro release, etc. Stability of protein molecules was accessed by SDS-PAGE. The antigenicity of protein HBsAg was determined by EIA and the functional stability of HA was evaluated by haemagglutination assay. Subsequently, in vivo study was carried out to study their feasibility as nasal vaccine carriers. A significant and perdurable immune response was obtained following in vivo administration of the developed formulations that was comparable with alum adsorbed HBsAg administered intramuscularly. The HA complexed liposomal formulations elicited sIgA in mucosal secretions and also demonstrated cellular immune response both of which are not induced in the case of alum adsorbed HBsAg vaccine. Further, the HA complexed liposomes produced higher immune response as compared to plain liposomes that might be due to higher uptake of former as evidenced in microscopy study of nasal tissues. The higher cellular response generated by HA complexed liposomes may be possibly due to characteristic pH dependent fusion property of HA protein.",
keywords = "HA, HBsAg, Liposomes, pH dependent fusion",
author = "Shailja Tiwari and Verma, {Sunil Kumar} and Agrawal, {Govind P.} and Vyas, {Suresh P.}",
year = "2011",
month = "7",
day = "15",
doi = "10.1016/j.ijpharm.2011.04.029",
language = "English (US)",
volume = "413",
pages = "211--219",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen

AU - Tiwari, Shailja

AU - Verma, Sunil Kumar

AU - Agrawal, Govind P.

AU - Vyas, Suresh P.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - The present work investigates prospective of recombinantly expressed influenza surface protein haemagglutinin (HA) complexed liposomes for intranasal delivery of HBsAg. Liposomes encapsulating HBsAg were prepared and complexed with HA. The prepared formulations were extensively characterized for vesicle size, polydispersity index, entrapment efficiency, HA complexation efficiency, in vitro release, etc. Stability of protein molecules was accessed by SDS-PAGE. The antigenicity of protein HBsAg was determined by EIA and the functional stability of HA was evaluated by haemagglutination assay. Subsequently, in vivo study was carried out to study their feasibility as nasal vaccine carriers. A significant and perdurable immune response was obtained following in vivo administration of the developed formulations that was comparable with alum adsorbed HBsAg administered intramuscularly. The HA complexed liposomal formulations elicited sIgA in mucosal secretions and also demonstrated cellular immune response both of which are not induced in the case of alum adsorbed HBsAg vaccine. Further, the HA complexed liposomes produced higher immune response as compared to plain liposomes that might be due to higher uptake of former as evidenced in microscopy study of nasal tissues. The higher cellular response generated by HA complexed liposomes may be possibly due to characteristic pH dependent fusion property of HA protein.

AB - The present work investigates prospective of recombinantly expressed influenza surface protein haemagglutinin (HA) complexed liposomes for intranasal delivery of HBsAg. Liposomes encapsulating HBsAg were prepared and complexed with HA. The prepared formulations were extensively characterized for vesicle size, polydispersity index, entrapment efficiency, HA complexation efficiency, in vitro release, etc. Stability of protein molecules was accessed by SDS-PAGE. The antigenicity of protein HBsAg was determined by EIA and the functional stability of HA was evaluated by haemagglutination assay. Subsequently, in vivo study was carried out to study their feasibility as nasal vaccine carriers. A significant and perdurable immune response was obtained following in vivo administration of the developed formulations that was comparable with alum adsorbed HBsAg administered intramuscularly. The HA complexed liposomal formulations elicited sIgA in mucosal secretions and also demonstrated cellular immune response both of which are not induced in the case of alum adsorbed HBsAg vaccine. Further, the HA complexed liposomes produced higher immune response as compared to plain liposomes that might be due to higher uptake of former as evidenced in microscopy study of nasal tissues. The higher cellular response generated by HA complexed liposomes may be possibly due to characteristic pH dependent fusion property of HA protein.

KW - HA

KW - HBsAg

KW - Liposomes

KW - pH dependent fusion

UR - http://www.scopus.com/inward/record.url?scp=79958012662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958012662&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2011.04.029

DO - 10.1016/j.ijpharm.2011.04.029

M3 - Article

C2 - 21540094

AN - SCOPUS:79958012662

VL - 413

SP - 211

EP - 219

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -